Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Annals of Neurology

Volumn 73, Issue 3, 2013, Pages 327-340

  Lublin, Fred D ^a   Cofield, Stacey S ^b   Cutter, Gary R ^b   Conwit, Robin ^c   Narayana, Ponnada A ^d   Nelson, Flavia ^e   Salter, Amber R ^b   Gustafson, Tarah ^a   Wolinsky, Jerry S ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCORING SYSTEM;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876473109     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23863     Document Type: Article

References (22)

1. Weiner HL,. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-248.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
3. Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5: 205-220.
4. Conway D, Cohen JA,. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9: 299-308.
5. Graber JJ, McGraw CA, Kimbrough D, et al. Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg 2010; 112: 583-591.
6. Lindsey J, Scott T, Lynch S, et al. The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 2012; 1: 81-86.
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
8. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
9. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II. MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators [see comments]. Neurology 2000; 54: 1734-1741.
10. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303.
11. Sajja BR, Datta S, He R, et al. Unified approach for multiple sclerosis lesion segmentation on brain MRI. Ann Biomed Eng 2006; 34: 142-151.
12. Datta S, Sajja BR, He R, et al. Segmentation and quantification of black holes in multiple sclerosis. Neuroimage 2006; 29: 467-474.
13. Tao G, He R, Datta S, et al. Symmetric inverse consistent nonlinear registration driven by mutual information. Comput Methods Programs Biomed 2009; 95: 105-115.
14. Inusah S, Sormani MP, Cofield SS, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010; 16: 1414-1421.
15. Lublin FD,. Disease activity free status in MS. Mult Scler Relat Disord 2012; 1: 6-7.
16. Khan O, Bao F, Shah M, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. J Neurol Sci 2012; 312: 7-12.
17. Hardmeier M, Wagenpfeil S, Freitag P, et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64: 236-240.
18. Khoury S, Bakshi R,. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Ann Neurol 2010; 68: 778-779.
19. Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN beta-1b. Neurology 2002; 59: 688-694.
20. Petzold A, Mondria T, Kuhle J, et al. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 2010; 68: 806-815.
21. Cohen JA, Chun J,. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.
22. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698-1704.